Loncastuximab Tesirine in Heavily Pretreated Patients with Diffuse Large B-cell Lymphoma, Including the Post-CAR-T Setting: A Meta-Analysis

Key Points

• Loncastuximab tesirine shows promising therapeutic efficacy in diffuse large b-cell lymphoma.
• The analysis included data from heavily pretreated patients and those in the post-car-t setting.
• Meta-analysis reveals significant improvements in treatment response rates for the evaluated population.
• This research highlights the need for ongoing exploration of targeted therapies in oncology.